Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Nivolumab (Opdivo) Drug Information

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - ScienceDirect

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Cancers, Free Full-Text

Nivolumab plus ipilimumab benefits patients with asymptomatic melanoma brain metastases

Advances in targeted therapy and immunotherapy for melanoma (Review)

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma

Frontiers Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan